[Form 4] KORU Medical Systems, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On June 30 2025, Ovintiv Inc. (OVV) director Ralph Izzo received 40 Deferred Share Units (DSUs) as a dividend equivalent, recorded in a Form 4 filing. Each DSU economically equals one common share and will be held until the director retires from the Board. The transaction was priced at $0, reflecting a non-cash, routine accrual of board compensation. Following the allocation, Izzo’s total direct ownership increases to 5,125 DSUs. No derivative exercises, open-market purchases, or sales occurred, and there is no indication of any change in corporate strategy or insider sentiment beyond ordinary board compensation.

Insights

Securities Analyst

TL;DR: Routine board compensation; negligible market impact.

The 40-unit DSU credit is an automatic dividend equivalent, adding roughly 0.8% to the director’s stake (5,085 → 5,125). No cash changed hands and there is no insider buying or selling signal. Such filings are customary and do not alter float or company liquidity, making the disclosure neutral for valuation or sentiment.

Corporate Governance Expert

TL;DR: Standard compliance filing; maintains alignment with shareholders.

Deferred Share Units link board compensation to shareholder returns, supporting governance best practices. However, the scale—40 units—is immaterial to ownership structure and voting power. The filing meets Section 16 requirements and discloses no new governance risk.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NJ 07430

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		A		6,284	A	$3.58	211,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams- Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ovintiv (OVV) disclose in the latest Form 4?

Director Ralph Izzo received 40 Deferred Share Units on 06/30/2025 as a dividend equivalent, raising his holding to 5,125 units.

Did the insider buy or sell Ovintiv shares for cash?

No. The transaction was a non-cash DSU allocation priced at $0, not an open-market trade.

How many Ovintiv shares does Ralph Izzo now beneficially own?

After the filing, Izzo directly holds 5,125 DSUs, each equivalent to one common share.

Does this Form 4 signal bullish or bearish insider sentiment?

Neither. It reflects routine board compensation with no voluntary purchase or sale of shares.

What is a Deferred Share Unit (DSU)?

A DSU is compensation that mirrors Ovintiv common stock and is typically settled in shares or cash when the director leaves the board, aligning interests with shareholders.

Were any derivative securities exercised or expired?

No derivative exercises or expirations were reported; only the addition of 40 DSUs was disclosed.